Shareholders Equity: The sum of preferred and common equity items.
Larimar Therapeutics, Inc. (LRMR) had Shareholders Equity of $127.38M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-31.28M |
|
-- |
|
-- |
|
$34.35M |
|
$-34.35M |
|
$1.57M |
|
$-32.78M |
|
$-32.78M |
|
$-32.78M |
|
$-32.78M |
|
$-32.78M |
|
$-32.78M |
|
$-34.35M |
|
$-34.63M |
|
103.88M |
|
103.88M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$160.67M |
|
$0.64M |
|
$4.63M |
|
$165.30M |
|
$34.17M |
|
-- |
|
$3.75M |
|
$37.92M |
|
$127.38M |
|
$127.38M |
|
|
Shareholders Equity |
$127.38M |
103.88M |
|
| Cash Flow Statement Financials | |
$-88.64M |
|
$-11.91M |
|
$107.68M |
|
$86.02M |
|
$93.14M |
|
$7.12M |
|
$4.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.70 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-88.77M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-25.74% |
|
-25.74% |
|
-19.83% |
|
-25.74% |
|
$1.23 |
|
$-0.85 |
|
$-0.85 |
|